Regeneron (REGN) Tops Q2 EPS by $1.18, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil drops $1 as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Regeneron Reports Second Quarter 2020 Financial and Operating Results
August 5, 2020 6:30 AM EDTTARRYTOWN, N.Y., Aug. 5, 2020 /PRNewswire/ --Â
Second quarter 2020 revenues increased 24% to $1.95 billion versus second quarter 2019(4) Second quarter 2020 EYLEA® U.S. net sales were $1.11 billion Second quarter 2020 Dupixent® global net sales(2), which are recorded by Sanofi, were $945 million Second quarter 2020 GAAP diluted EPS was $7.61 and non-GAAP diluted EPS(1) was $7.16 Initiated Phase 2 and Phase 3 clinical trials of REGN-COV2 for the treatment and prevention of COVID-19 FDA approved Dupixent for children aged 6 to 11 years with moderate-to-severe atopic dermatitis Dupixent eosinophilic... More